



## Product Information

**Product ID** E2003

**CAS No.** 154598-52-4

**Chemical Name**

**Synonym**

**Formula** C<sub>14</sub>H<sub>9</sub>ClF<sub>3</sub>NO<sub>2</sub>

**Formula Wt.** 315.67

**Melting Point** 139-141 °C


**Purity** ≥99%

**Solubility** Ethanol (20 mg/ml), DMF (20 mg/ml), DMSO (14 mg/ml)

**Store Temp** Ambient

**Ship Temp** Ambient

**Description** Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits antiviral and anticancer activities. Efavirenz is clinically used to treat HIV infection; it induces autophagy in neurons, leading to some centrally mediated toxicity. In various cancer cell lines, efavirenz inhibits cellular proliferation and increases activation of p53.



## Pricing and Availability

*Bulk quantities available upon request*

| Product ID | Size  | List Price |
|------------|-------|------------|
| E2003      | 5 mg  | \$68.30    |
| E2003      | 10 mg | \$89.30    |
| E2003      | 25 mg | \$152.30   |
| E2003      | 50 mg | \$236.30   |

**References** Schauer GD, Huber KD, Leuba SH, et al. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. *Nucleic Acids Res.* 2015 Feb 1;42(18):11687-96. PMID: 25232099.

Purnell PR, Fox HS. Efavirenz induces neuronal autophagy and mitochondrial alterations. *J Pharmacol Exp Ther.* 2014 Nov;351(2):250-8. PMID: 25161171.

Hecht M, Harrer T, Büttner M, et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. *AIDS.* 2013 Aug 24;27(13):2031-40. PMID: 23612009.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.